⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18721616 | 1.00 | — | — | |
| SCHEMBL16417970 | 1.00 | — | — | |
| SCHEMBL635673 | 1.00 | — | — | |
| SCHEMBL13807849 | 0.81 | — | — | |
| SCHEMBL2051796 | 0.78 | — | — | |
| SCHEMBL3414997 | 0.78 | — | — | |
| SCHEMBL18881748 | 0.77 | — | — | |
| SCHEMBL7931844 | 0.77 | — | — | |
| SCHEMBL12868625 | 0.77 | — | — | |
| SCHEMBL2630593 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3825312-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Pharmasset LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10335409-B2 | Inhibitors of hepatitis C virus | GILEAD PHARMASSET LLC (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3492464-A1 | INTERMEDIATES FOR PREPARING INHIBITORS OF HEPATITIS C VIRUS | Gilead Sciences, Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-2970335-B1 | MACROCYCLIC AND BICYCLIC INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-05-08 | — | — | EP | disclosed |
| EP-3159345-B1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES INC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162905-A1 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2018-06-14 | — | — | US | disclosed |
| US-20170313745-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290827-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD PHARMASSET LLC | 2017-10-12 | — | — | US | disclosed |
| US-20090202486-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197888-A1 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009094443-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094438-A1 | HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009076166-A2 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076173-A2 | FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090155210-A1 | OXIMYL HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2009064975-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |